Itch is a major symptom of many chronic skin diseases that can exacerbate inflammation by provoking excessive scratching and causing skin damage. Here we develop a novel technology to control itch through molecular guided delivery of a phototoxic agent and near 
Introduction
Itch is a cutaneous sensory perception defined by the behavioral response it elicits: an urgent need to scratch 1 . When itching becomes pathological, it can be irritating and distressful and have a dramatic impact on quality of life 2 . Chronic itch generates a recurrent cycle whereby the more the skin is scratched, the more it itches 3 . In turn, this may lead to serious damage to the skin barrier and thereby an increased risk of infection 3 . There are many itch-associated diseases such as Atopic Dermatitis (AD) and psoriasis that respond poorly to current therapies 4 . Identifying novel strategies to reduce itching is therefore critical and requires a deeper understanding of the underlying mechanisms.
Although several key molecules involved in transducing itch sensation have recently been described, the cellular and molecular mechanisms that drive chronic itch are not fully understood. The transduction of itch begins in the skin where a network of different cell types, such as keratinocytes, sensory nerves and immune cells respond to exogenous or endogenous pruritogens and initiate the cascade which ends with the scratch response 5 .
Two major itch pathways have been described: the histaminergic pathway which is mediated by histamine 6 and the non-histaminergic pathway which includes a plethora of other itch mediators, such as chloroquine, neuropeptides and inflammatory cytokines 7 . It is becoming increasingly apparent that anti-histaminergic drugs are often ineffective against many chronic itch conditions such as Atopic Dermatitis and psoriasis 8, 9 . Attention has now turned to non-histaminergic pathways to control itch sensation under pathological conditions 10 .
Amongst anti-histamine resistant itch mediators, the cytokine Interleukin 31 (IL-31) has recently attracted much attention as a novel target molecule for chronic itch therapy 11 . IL-31 is a cytokine with a prominent skin tropism that is produced preferentially by T helpertype 2 cells 12 . It signals through a heterodimeric receptor composed of IL31RA and OSMR which are expressed in epithelial cells, keratinocytes and sensory neurons 13, 14 . Transgenic mice overexpressing IL-31 develop severe pruritus, alopecia and skin lesions that resemble lesioned skin from patients with atopic dermatitis 11 . Moreover, numerous studies have reported an association of IL-31 with inflammatory skin diseases with a severe pruritic component such as atopic dermatitis, prurigo nodularis, allergic contact dermatitis, and cutaneous T-cell lymphoma [15] [16] [17] [18] . For example, IL-31 mRNA is up-regulated in human patients and mouse models of atopic dermatitis 15, 19 and increased levels of IL31 correlate with disease severity 20, 21 . A common IL31 haplotype has also been associated with nonatopic eczema in three independent European populations, marking this as the first genetic risk factor for non-atopic eczema 22 . Furthermore, mutations in the IL31 receptors IL31RA
and OSMR underlie Familial Primary Localized Cutaneous Amyloidosis (FPLCA), a hereditary skin disorder characterized by the deposition of amyloid in the dermal papilla and severe pruritus [23] [24] [25] [26] [27] . Intriguingly, it has been suggested that the major pathology evoked by IL-31 is to induce pruritus, rather than directly causing skin lesions per se 28 . Thus, therapies which reduce scratching and break the cycle of itch and disruption of the skin's barrier function 29 may be the most effective strategies for improving the quality of life for patients with chronic pruritic disease 3 . Indeed, recent phase I and 2 clinical trials of a humanized antibody against IL31RA (Nemolizumab, CIM331) have shown some promise in improving pruritus in patients with moderate to severe atopic dermatitis 30, 31 .
Here we have asked whether the IL31 ligand may serve as an alternative means of accessing pathways in the skin which provoke itch. Because IL31 receptors are expressed by itch sensing cells, we reasoned that conjugation of the IL31 ligand to a photosensitizer may allow for specific delivery of phototoxic complexes to these cells in the skin, and thus enable light activated suppression of itch sensation at its source. To achieve this aim we generated a recombinant IL31 fusion protein with a SNAP tag placed at its C-terminus that would allow for its chemical modification with benzylguanine (BG) derivatized probes. We demonstrate that IL31 SNAP is functional and can be conjugated to a photosensitizer to control IL31-induced scratching behavior. We further identify an IL31 mutant (IL31 K138A ) that binds to keratinocytes but no longer provokes signaling or scratching. Delivery of IL31 K138A-SNAP -IR700 to the skin and subsequent near infrared illumination inhibits acute scratching and reverses behavioral and dermatological indicators in mouse models of Atopic Dermatitis and FPLCA. Intriguingly, this effect appears to be dependent upon retraction of sensory fibers from the epidermis of the skin, thus breaking the cycle of itch and disruption of the skin's barrier function.
Results

Generation and characterization of IL31 SNAP
Recombinant IL31 was produced with a C-terminal fusion of SNAP (IL31 SNAP ) in E. Coli. 
IL31 mediated photoablation
To manipulate IL31 receptor expressing cells in vivo, we reasoned that IL31 SNAP may allow for targeted photoablation of these cells through delivery of a photosensitizing agent. We synthesized a benzylguanine modified derivative of the highly potent near-infrared photosensitizer IRDye®700DX phthalocyanine (IR700) and conjugated it in vitro to IL31 SNAP 32 . Application of IL31 SNAP -IR700 to keratinocytes followed by 1 minute illumination provoked substantial cell death (Figure 1e ) that was not evident in keratinocytes only treated with IR700 + illumination (Figure 1f ) or in keratinocytes from IL31RA -/-mice ( Figure 1g ). We further examined photosensitizer effects in vivo by injecting IL31 SNAP -IR700 subcutaneously, applying near infrared light to the skin, and monitoring IL31 evoked scratching behavior.
Strikingly, a progressive decrease in scratching bouts was observed when IL31 SNAP -IR700 was injected for three consecutive days and the skin illuminated (Figure 1h ).
Generation and characterization of a non-signaling IL31 mutant
A conceptual problem of using IL31 SNAP therapeutically is that it in itself evokes itch. We therefore sought to engineer IL31 SNAP to obtain a ligand that still binds to IL31 receptor complex but no longer promotes signaling. From a previous structural study 33 we selected an IL31 point mutant IL31 K134A that was reported to exhibit reduced signaling in cells expressing human IL31 receptors. We generated a recombinant mouse IL31 K138A-SNAP fusion protein (orthologous to human IL31 K134A ), labelled it with BG-Surface549 and applied it to keratinocytes. Pronounced fluorescence was evident in cells from wildtype mice treated with fluorescent IL31 K138A-SNAP (Figure 2a) , at a similar concentration range to that observed with IL31 SNAP (Supplementary Figure 2a-k) . Importantly, such signal was not present in IL31RA -/-keratinocytes ( Figure 2b ). We further assessed cellular signaling pathways activated by IL31 SNAP and IL31 K138A-SNAP in the skin by examining levels of phosphorylated Akt, pMAPK and pSTAT3 which have all been previously implicated in IL31 downstream signaling 14, 33, 34 . Mice were injected subcutaneously with IL31 SNAP and IL31 K138A-SNAP and skin harvested 1 hour later for immunoblot analysis. We observed an increase in phosphorylation of the downstream pathways in skin injected with IL31 SNAP and this increase was absent in skin injected with IL31 K138A-SNAP (Figure 2c and d) . As a final test for the functional activity of IL31 K138A-SNAP , we assayed its capacity to provoke scratching behavior in mice. In contrast to IL31 SNAP which induced robust scratching when injected intradermal, IL31 K138A-SNAP did not evoke any scratching above baseline levels in mice (Figure 2e) . Thus, the engineered ligand IL31 K138A-SNAP may offer a powerful means of targeting cells involved in itch without triggering itch in itself.
IL31 K138A-SNAP -IR700 mediated photoablation and acute itch
To characterize IL31 K138A-SNAP mediated photoablation in vivo, we first tested its efficacy at alleviating IL31 provoked itch. Mice were treated for three consecutive days with IL31 K138A-SNAP -IR700 and the skin was illuminated with near-IR light. Strikingly, IL31-induced scratching behavior was abolished in these animals (Figure 2f ), and this persisted throughout an 8 week observation period (Supplementary Figure 2l) . In control mice that received an IL31 K138A-SNAP -IR700 injection but were not illuminated, we observed no reduction in IL31-evoked scratching (Figure 2f ). We next tested the effects of photoablation on scratching provoked by other acutely applied pruritogens. Intriguingly, IL31 K138A-SNAP guided photoablation had no significant effect on Histamine, LY344864 (a serotonin 5-HT1F receptor agonist) or Chloroquine evoked itch (Figure 2f ). Finally, to assess the specificity of photoablation to itch sensation, we examined other sensory modalities after treatment.
Using the Hot Plate test to assay thermal sensitivity (Figure 2g ) and calibrated von Frey filaments to measure mechanical sensitivity (Figure 2h ), we observed no difference in response properties of treated mice, indicating that IL31 guided laser ablation is indeed a selective and effective means of disrupting IL31 evoked itch.
IL31 K138A-SNAP -IR700 mediated photoablation and Atopic Dermatitis
We examined the effects of IL31 K138A-SNAP -IR700 ablation on inflammatory itch using the For IL31 K138A -guided photoablation to have therapeutic relevance, it must also be effective in reversing already established skin inflammation. We therefore treated mice with Calcipotriol for 7 days until severe symptoms were evident. IL31 K138A-SNAP -IR700 was then injected subcutaneously and near IR light applied to the skin for three consecutive days. To further improve the clinical applicability of IL31 K138A guided photoablation, we sought to develop a formulation that would allow for topical, pain-free application of IL31 K138A-SNAP -IR700. We selected a water-in-oil micro-emulsion preparation based upon previous evidence that this type of formulation can deliver high molecular weight proteins across the dermal barrier 36 . IL31 K138A-SNAP -IR700 was loaded into the aqueous phase of the microemulsion, applied topically, and 20 minutes later skin was illuminated with near IR light. 
Generation of a mouse model of the genetic skin disorder Familial Primary Localized
Cutaneous Amyloidosis (FPLCA) FPLCA is a rare, hereditary skin disorder driven by mutations in the IL31 receptors IL31RA and OSMR, and characterized by severe pruritus 37 . We sought to generate a mouse model of FPLCA to further test the therapeutic potential of IL31 K138A-SNAP photoablation in a more chronic and challenging clinical setting. We used CRISPR/Cas9 technology to knock-in an S476F mutation into the Il31ra locus, orthologous to the human FPLCA mutation IL31RA S521F 26 . From 14 offspring, we obtained one IL31RA -/-mouse and one IL31RA S476F mouse that were confirmed by sequencing (Supplementary Figure 4b) . Upon expansion of the IL31RA S476F line we observed that both heterozygote and homozygous mice spontaneously developed phenotypes that resembled symptoms of FPLCA. These included a significant increase in spontaneous scratching behavior (Supplementary Figure 5a 
IL31 K138A-SNAP -IR700 mediated photoablation in a mouse model of psoriasis
To investigate further the scope of IL31 K138A mediated photoablation, we tested its effectiveness in an additional skin disorder, psoriasis, which is not believed to have a strong dependence upon IL31 signaling 38 . We used the Aldara mouse model of psoriasis where Aldara cream, containing the Toll-like receptor 7-ligand Imiquimod, is applied to the skin. In 
Mechanism of action of IL31 K138A-SNAP -mediated photoablation
To investigate the mechanism underlying IL31 K138A-SNAP -IR700 mediated photoablation we focused our attention on the three major cell populations which express IL31 receptor complexes in the skin; cutaneous dendritic cells (specifically Langerhans cells), keratinocytes and free nerve endings innervating the skin 13, [39] [40] [41] . Again, we performed photoablation by applying IL31 K138A-SNAP -IR700 to the back skin and then analyzed samples from illuminated or control non-illuminated skin at 1 day, 1 week or 1 month post treatment. is sufficient to reduce scratching behavior, we performed photoablation directly on the proximal sciatic nerve. IL31 K138A-SNAP -IR700 was applied to the sciatic nerve at mid-thigh level and scratching/biting behavior evoked by IL31 injection of the innervation territory in the calf was monitored. Upon illumination of the sciatic nerve we observed a significant reduction in IL31 evoked behavior that was not evident in non-illuminated control animals.
Thus, IL31 K138A-SNAP guided photoablation triggers retraction of pruriceptive sensory neurons in the skin, thereby alleviating scratching and the chain of events that leads to inflammation.
Discussion
Chronic itch is a common and often overlooked condition that is difficult to treat and exerts a substantial societal burden 42, 43 . Here we describe a novel approach to control itch that is highly effective in mouse models of Atopic Dermatitis and the genetic skin disease FPLCA.
Exploiting the natural selectivity of the IL31 ligand to its receptors on itch sensing cells in the skin, we design an IL31 derivative that enables delivery of a photosensitizer to itch sensors in vivo without causing itch in itself. Through illumination of treated skin, we are able to reverse behavioral and histological indicators of atopic dermatitis and FPLCA from a single treatment regime. We demonstrate that this is dependent upon photosensitizer induced retraction of itch sensing neurons from the epidermis, and thus silencing of the neuronal driver of scratching at its source in the skin.
Current therapeutic options for alleviating chronic itch rely on treatments that aim at controlling skin barrier function and inflammation rather than targeting itch itself 44 . For example, in atopic dermatitis patients, initial treatment involves the use of topical moisturizers, emollients and corticosteroids, followed by systemic treatments such as oral immunosuppressants or UV therapy if disease worsens 4, 43 . All of these approaches suffer from severe adverse effects, and a significant problem in treating chronic itch is continued adherence to therapy, with most patients abandoning treatments within a year 44 . Recently, the first mechanism based targeted therapy for atopic dermatitis was approved in the US, a human monoclonal antibody against the interleukin-4 receptor alpha subunit named Dupixent [45] [46] [47] . In addition, further clinical trials are also underway for a humanized antibody against IL31RA (Nemolizumab) 30, 31 , highlighting the potential of biologics in treating itch. It is currently not known what the long term effectiveness and safety of these treatments will be, and the cost of repeated treatment is likely to restrict their use to only the more severe cases of atopic dermatitis 45, 48 .
The photoablation approach we describe here has several conceptual differences to the aforementioned strategies for treating pruritic diseases. Firstly, photoablation targets cells rather than single molecules, thus bypassing the enormous molecular complexity that underlies itch. A major difficulty in selecting targets for new antipruritic medications is the molecular redundancy that is inherent to itch sensation. By inactivating the integrating unit of itch, the sensory neuron, rather than individual molecules in the itch pathway, we circumvent this redundancy. Secondly, our data indicates that a single treatment regime with photosensitizer and light allows for long-lasting alleviation of scratching, thus facilitating skin healing. Indeed we observed reversal of IL31-evoked itch that persisted throughout an 8 week observation period, and in the FPLCA model, behavioral and histological indicators were normalized for at least 3 months. In the Calcipotriol model of dermatitis we also observed recovery that continued for the maximal ethically acceptable observation period.
Thirdly, through local, on-demand application of ligand-photosensitizer complex and light, we are able to achieve precise control of drug action, thus avoiding systemic side effects and allowing therapy to be tuned to disease severity. Further development could also allow for systemic delivery of the photosensitizer complex combined with local application of light.
Finally, we have developed an engineered ligand, rather than an antibody or small molecule to target cells. We chose this approach because we wished to exploit the naturally high affinity of IL31 to its receptor, and because of ease of production of recombinant ligand. A similar approach could therefore by readily adapted to other cell surface receptors such as for example IL17 receptors in psoriasis, without the need for extensive screening to identify novel binders. Moreover, existing antibodies or small molecules that target membrane receptors could also be co-opted to deliver photosensitizers, analogous to delivery methods developed for photodynamic therapy of cancer 49 .
Beyond atopic dermatitis, IL31 has been implicated in a number of other pruritic diseases such as prurigo nodularis, cutaneous T-cell lymphoma, and chronic idiopathic pruritus 15, 17, 18, 50 , and targeted photoablation could conceivably also have therapeutic efficacy in these disorders. To further examine the scope of IL31 mediated photoablation, we chose to focus on the rare genetic skin disease FPLCA, which is driven by mutations in the IL31 receptor complex [24] [25] [26] [27] . FPLCA is characterized by severe pruritus and localized deposition of amyloid in the dermal papilla 23 , both of which are highly distressing and impact profoundly on the quality of life of patients. There are no effective treatment options for FPLCA and management of the disorder relies upon topical application of corticosteroids, UV phototherapy and systemic treatment with immunosuppressants 23 . Here we describe the first mouse model of FPLCA, and demonstrate that mutant IL31RA S476F mice develop phenotypes that are remarkably similar to human symptoms. Thus we observed a significant increase in spontaneous scratching behavior, damage and inflammation of the skin, and deposition of amyloid. We did not explore in detail the molecular mechanisms that underlie FPLCA, instead focusing on gauging the therapeutic potential of IL31 K138A mediated photoablation. Indeed we found that a single treatment regime led to a substantial improvement in disease progression that persisted throughout the 3 month observation period. We now expect that the IL31RA S476F mouse model will allow for further mechanistic investigations, and will also enable preclinical testing of other emerging IL31 orientated medications such as humanized IL31RA antibodies 30, 31 and JAK inhibitors 42, 51 for treating FPLCA.
IL31 receptor complexes are expressed by cutaneous dendritic cells, keratinocytes, and free nerve endings in the skin 13, [39] [40] [41] , and hypothetically, IL31 K138A mediated photoablation could induce cell toxicity in any of these cell types. Intriguingly, our analysis of these populations post ablation points towards a selective and sustained loss of neuronal innervation by IL31 K138A -IR700. This raises the question as to why dendritic cells and keratinocytes are spared by the treatment. One possibility is that there is a transient loss of these cells which we are not able to detect because of ongoing cell turnover and re-infiltration of the skin.
However, we did not observe any increase in TUNEL positive cells in the skin after photoablation suggesting that there is not a reduction in these cells through apoptosis. An alternative explanation is that sensory neurons, as excitable cells, are more susceptible to photosensitizer induced damage than dendritic cells or keratinocytes. Indeed, we have previously observed that exposure of sensory neurons to the photosensitizer fluorescein leads to a rapid loss of action potential firing and an increase in resting membrane potential 52 , which could act as an initial trigger to promote neuronal toxicity.
Our data also place sensory neurons as a critical integration point in the transduction of inflammatory itch, and support growing evidence that neurons represent an attractive target for treating pruritic skin diseases 1, 42, 53 . Of note, only a small proportion of sensory neurons express IL31 receptors [54] [55] [56] , and together with previous genetic ablation experiments 54 our analysis indicates that these neurons are not overtly sensitive to acute application of other pruritogens such as histamine and chloroquine. Intriguingly, recent evidence indicates that these neurons are sensitized by activation of interleukin-4 receptor alpha (the target for the human monoclonal antibody Dupixent), and JAK1 signaling, and that this may promote their involvement in inflammatory itch 42 . Indeed, atopic dermatitis is known to have a prominent neuronal component 5, 57 , and it has also been argued the FPLCA could represent a neurodermatitis rather than a primary disorder of keratinoctyes 25 . Data presented here suggest that IL31RA expressing sensory neurons are the key drivers of these disorders, and that their removal through photoablation is a powerful means of reversing disease progression.
Long-term elimination of the sensory nerve endings that signal itch could be considered a relatively excessive measure for treating pruritus. However, several other therapies share similar functional principles to IL31 K138A mediated photoablation but without the selectivity that ligand targeting offers. These include the use of psoralens as photosensitizers in UV therapy (PUVA) 58 , and the topical application of capsaicin [59] [60] [61] , both of which promote the retraction of nerve fibers in the skin 62, 63 . These treatments are however associated with adverse effects such as burning pain, increased itchiness and erythema, limiting patient compliance 58, 64 . Moreover, non-selective denervation may also lead to a loss of other sensations in addition to itch. By targeting directly a subset of pruriceptors using an engineered ligand and near infrared illumination we circumvent these issues, allowing for local on demand treatment of itch. Further development of the technology to target other membrane receptors and neuronal subsets may allow for treatment of a broad range of sensory disorders spanning itch and pain.
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Methods
Animals
Wild type, IL31RA -/-, and IL31RA S476F mice were used at age of 8-10 weeks for all the behavioral studies. 1-3 day-old mice were used for primary keratinocyte culture. All mice were bred and maintained at the EMBL Neurobiology and Epigenetic Unit, Rome, in accordance with Italian legislation (Art. 9, 27. Jan 1992, no 116) under license from the Italian Ministry of Health, and in compliance with the ARRIVE guidelines. IL31RA -/-, and IL31RA S476F mice have been deposited in the European Mouse Mutant Archive.
Production of recombinant IL31 SNAP and IL31 K138A-SNAP
cDNAs for murine IL31 and SNAP tag were cloned into pETM-11 vector and expressed in E.Coli as fusion protein, carrying a His6-tag at the N-terminus. To generate the mutant IL31 K138A-SNAP , site directed mutagenesis was performed according to the manufacturer's instruction (Agilent, #200555). The proteins were isolated from inclusion bodies, solubilized, refolded, and purified using a Ni-NTA resin (Qiagen, #30210). Eluted fractions were then pooled, concentrated and stored for further analysis.
Synthesis of BG-IR700
3mg of IRDye®700DX N-hydroxysuccinimide ester fluorophore (LI-COR Biosciences GmbH, Bad Homburg, Germany) were dissolved in 150µl DMSO and treated with 1.5mg BG-PEG11-NH2 and 5µl diisopropylethylamine. After 1h, the product BG-PEG11-IRDye®700DX was purified by HPLC using a Waters Sunfire Prep C18 OBD 5µM; 19 x 150 mm column using 0.1M triethylammonium acetate (TEAA)] (pH 7.0) and 0.1M TEAA in water/acetonitrile 3:7 (pH 7.0) as mobile phases A and B, respectively. A linear gradient from 100% A to 100% B within 30 minutes was used. The fractions containing the product were lyophilized.
Primary Keratinocyte culture
Primary keratinocytes were isolated from 1-3 day-old wild type, IL31RA -/-and IL31RA S476F mice as previously described 65 . Briefly, newborn mouse skin was removed and incubated flat in cold and freshly thawed trypsin overnight, at 4ºC, with the dermis side down. The next day, epidermis was peeled off, triturated and keratinocytes were cultured in serum free media (Invitrogen #10744-019) on Collagen I (Sigma # 122-20) -coated dishes (Ibidi #81151). All experiments were performed on 48-72 hours cultured cells.
In-vitro labeling
For keratinocyte labelling, 1 µM IL31 SNAP or IL31 K138A-SNAP was coupled with 3 µM BG549surf (NEB # S9112) for 1 hour at 37ºC in CIB buffer (NaCl 140 mM; KCl 4 mM; CaCl2 2 mM; MgCl2 1 mM; NaOH 4.55 mM; Glucose 5 mM; HEPES 10 mM; pH 7.4). Cells from wild type or IL31RA -/-or IL31RA S476F mice were incubated with the coupling reaction for 15-20 minutes at 37ºC, then washed 3 times in CIB. 1µg/ml Hoechst was used for nuclear staining. All images were visualized with a Leica SP5 confocal microscope.
In-vitro photo-ablation
1µM IL31 SNAP and 3µM IR700 were coupled for 1 hour at 37ºC. The coupling reaction was applied for 15-20 minutes at 37 o C on primary wild type and IL31RA -/-keratinocytes. Cells were then exposed to near infra-red light (680nm) at 40J/cm 2 for 1 minutes. 24 hours after light exposure cell death was assessed by Propidium Iodide (PI) staining (Invitrogen # P3566) and cells were imaged with a Widefield Leica microscope DMI6000B.
In-vivo photo-ablation using injection or micro emulsion as delivery system
The skin at the nape of the neck of wildtype and IL31RA -/-mice was shaved and injected with 5 µM IL31 SNAP or IL31 K138A-SNAP coupled to 15 µM IR700 in a 50 µl volume. 20 minutes after the injection, near infra-red light (680nm) at 200 J/cm 2 was applied on the injection site for 2 minutes. This procedure was repeated for 3 consecutive days. For von Frey and Hot Plate tests, this procedure was performed on the hind paw using a 20 µl injection volume.
All the behavioral experiments were performed 1 week after the last injection.
The micro emulsion was prepared as already described 36 . Briefly, all the components were assembled as follow: Caprylic Triglyceride 81gr; Glyceryl Monocaprylate 27gr; Polysorbate80 12gr; Sorbitan Monooleate 8gr. The micro emulsion was mixed with the coupling reaction (IL31 K138A-SNAP + IR700) at 1:1 ratio in 10 µl volume with 5 µM as IL31 K138A-SNAP final concentration. The mixture was then applied on Calcipotriol-treated mice and FPLCA mice following the same procedure described above for the injection.
Immunofluorescence
Back skin from 8-10 week-old Black 6/J male mice was dissected and fixed in PFA 4% overnight at 4ºC. The next day, skin samples were transferred in 30% sucrose for 3-4 hours and frozen in OCT. 40-µm sections were cut with a cryostat and stained for Rabbit anti- Pgp9.5 + fibers quantitation, the region of dermis / epidermis junction was analyzed and only the intra-epidermal free nerve endings per section were considered for counting 66 .
Immunohistochemistry
Paraffin-embedded back skin from 8-10 week-old Black 6/J or FPLCA male mice was sectioned at 6µm thickness with a microtome. Sections were deparaffinized, hydrated to 
Flow cytometry
To analyze differences in Langerhans cell levels upon photoablation, we performed flow cytometry. The whole back skin of wildtype 8-10 week-old Black 6/J male mice was collected at different time points post photoablation (1 day, 1 week, 1 month post) and cutaneous dendritic cells were isolated as previously described 67 . Briefly, the back skin was cut in 1cm pieces and digested overnight at 4º C in 1 mg/ml Dispase II (Roche # 4492078001). The next day, the skin pieces were further digested in an enzymatic solution of 1 mg/ml Collagenase IV (Worthington # CLS4 LS004188) and 0,5 mg/ml DNase (Sigma # DN25) at 37ºC for 2 hours; finally, the cell suspension was filtered with a 100 µm cell strainer, washed with PBS + 0,5 M EDTA + 2% FBS and centrifuged at 1700 rpm for 5 minutes at 8ºC. Cells were re-suspended in HBSS + 5mM MgCl2 + 100 µg/ml DNase + 1% BSA and labelled with 0,5 µg /1x10 6 67, 68 . The experiments were performed using FACS Aria instrument and data were analyzed using FlowJo software.
SDS-Page and Western blot
To assess the coupling reaction, 1 and 2 µM IL31 K138A-SNAP was coupled with 3 and 6 µM 
Behavioral testing
Scratching behavior
To evaluate the scratching response, 8-10 week-old male wild-type or IL31RA -/-or IL31RA S476F mice were shaved at the nape of the neck, placed in Plexiglas chambers to acclimatize (30 minutes), videotaped for 30 minutes and scratching bouts were counted.
One bout was defined as an event of scratching lasting from when the animal lifted the hind paw to scratch until it returned it to the floor or started licking it. For IL31-mediated itch, 5µM IL31 SNAP or IL31 K138A-SNAP or native IL31 (Peprotech, #210-31) were injected intradermal for 1-3 days depending on the experiment. Regarding other itch-mediators, 10 mM histamine (Sigma, #H7250), 1 mM LY344864 (Abcam, #ab120592) or 12,5 mM Chloroquine (Sigma, #C6628) were injected into the back skin of wild type mice previously injected with 5 µM IL31 K138A-SNAP + 15 µM IR700 with or without near IR illumination. The injection of pruritogens was done 1 week after the last treatment. For long-term reversal IL31 evoked scratching, IL31 was injected 1 day after the last day of illumination and then every week for 8 weeks.
4µg/ml Calcipotriol-mediated itch was assessed at different time points to monitor dermatitis development, with or without near IR illumination.
von Frey test
Mice were habituated on an elevated platform with a mesh floor for 30 minutes. The plantar side of the hind paw was stimulated with calibrated von-Frey filaments (North coast medical #NC12775-99) to assess baseline levels of mechanical sensitivity. The hind paw of wildtype mice were then injected for 3 consecutive days with IL31 K138A-SNAP coupled with IR700 with or without near IR light illumination. The stimulation with von-Frey filaments was then repeated 1 week after the last photoablation. The 50% paw withdrawal thresholds were calculated using the Up-Down method 69 .
Hot Plate test
Mice were injected for 3 consecutive days with IL31 K138A-SNAP coupled with IR700 with or without near IR light illumination. 1 week after the last injection, mice were placed on top of a Hot Plate (Ugo Basile #35150) that was preset to 52 o C and the latency to response as distinguished by flicking or licking of the hind paw was observed. In order to avoid injury to the mice, a cutoff of 30 seconds was set.
Mouse model for Atopic Dermatitis (AD)
4 µg/ml of the vitamin D3 analogue Calcipotriol (Tocris #2700) was applied topically to the shaved back skin of the mice for 14 or 21 days, depending on the experiment. 0,002% DMSO was applied as vehicle control for 14 days. Atopic dermatitis development was assessed by scratching behavior over a 30 minute-recording period, skin thickness measurement using a Caliper and histological analysis for cellular infiltration of the treated skin by Hematoxylin & Eosin staining.
Mouse model for Familiar Primary Localized Cutaneous Amyloidosis (FPLCA)
The IL31RA S476F mouse was generated using cloning-free CRISPR/Cas9 technology as previously described 70 . Briefly, the knock-in point mutation in Il31ra locus, responsible for the amino acid substitution S476F 26 
Mouse model for psoriasis
62,5 mg Aldara 5% corresponding to 3,125 mg of active component was applied topically to the back skin for 7-10 days as previously described 71 . The development of the disease was monitored and graded using a modified human scoring system Psoriasis Area Severity Index (PASI) which considers skin thickness, erythema and scaling. Scratching behavior was also recorded. After 7-10 days, mice were sacrificed and skin was collected for histological analysis.
Nerve photoablation
The sciatic nerve innervating the hind paw/calf region of 8-10 week-old male mice was treated with 30 ng/µl TPA to permeabilize the epineural sheath for 15 minutes; then 5 µM IL31 K138A-SNAP +15 µM IR700 was applied on the exposed nerve and after 10-15 minutes, near IR light was applied for 45 seconds, except in the control group. Starting from 3 days post treatment, mice were injected with 5 µM IL31 SNAP at different days in the paw/calf level, and monitored for scratching expressed as time spent in biting at the injected area.
Statistical analysis
All statistical data are presented as Standard error of the mean (SEM) along with the number of samples analyzed (n). Student's t-test and/or analysis of variance ANOVA followed by the appropriate postHoc test were used. Statistical significance was assumed at p<0.05. ** ** ** Figure 5 
